Small molecule targeting the Rac1-NOX2 interaction prevents collagen-related peptide and thrombin-induced reactive oxygen species generation and platelet activation

J Thromb Haemost. 2018 Oct;16(10):2083-2096. doi: 10.1111/jth.14240. Epub 2018 Aug 13.

Abstract

Essentials Reactive oxygen species (ROS) generation by NOX2 plays a critical role in platelet activation. Rac1 regulation of NOX2 is important for ROS generation. Small molecule inhibitor of the Rac1-p67phox interaction prevents platelet activation. Pharmacologic targeting of Rac1-NOX2 axis can be a viable approach for antithrombotic therapy.

Summary: Background Platelets from patients with X-linked chronic granulomatous disease or mice deficient in nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidase isoform NOX2 exhibit diminished reactive oxygen species (ROS) generation and platelet activation. Binding of Rac1 GTPase to p67phox plays a critical role in NOX2 activation by facilitating the assembly of the NOX2 enzyme complex. Objective We tested the hypothesis that Phox-I, a rationally designed small molecule inhibitor of Rac-p67phox interaction, may serve as an antithrombosis agent by suppressing ROS production and platelet activation. Results Collagen-related peptide (CRP) induced ROS generation in a time-dependent manner. Platelets from Rac1-/- mice or human platelets treated with NSC23766, a specific Rac inhibitor, produced significantly less ROS in response to CRP. Treatment of platelets with Phox-I inhibited diverse CRP-induced responses, including: (i) ROS generation; (ii) release of P-selectin; (iii) secretion of ATP; (iv) platelet aggregation; and (v) phosphorylation of Akt. Similarly, incubation of platelets with Phox-I inhibited thrombin-induced: (i) secretion of ATP; (ii) platelet aggregation; (iii) rise in cytosolic calcium; and (iv) phosphorylation of Akt. In mouse models, intraperitoneal administration of Phox-I inhibited: (i) collagen-induced platelet aggregation without affecting the tail bleeding time and (ii) in vivo platelet adhesion/accumulation at the laser injury sites on the saphenous vein without affecting the time for complete cessation of blood loss. Conclusions Small molecule targeting of the Rac1-p67phox interaction may present an antithrombosis regimen by preventing GPVI- and non-GPVI-mediated NOX2 activation, ROS generation and platelet function without affecting the bleeding time.

Keywords: NADPH oxidase; Rac1 GTP-binding protein; platelet activation; reactive oxygen species; thrombosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Platelets / drug effects*
  • Blood Platelets / enzymology
  • Calcium Signaling / drug effects
  • Carrier Proteins / pharmacology
  • Enzyme Inhibitors / pharmacology*
  • Fibrinolytic Agents / pharmacology*
  • Humans
  • Mice, Knockout
  • NADPH Oxidase 2 / antagonists & inhibitors*
  • NADPH Oxidase 2 / blood
  • Neuropeptides / antagonists & inhibitors*
  • Neuropeptides / blood
  • Neuropeptides / genetics
  • Peptides / pharmacology
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Membrane Glycoproteins / metabolism
  • Reactive Oxygen Species / blood*
  • Thrombin / pharmacology
  • rac1 GTP-Binding Protein / antagonists & inhibitors*
  • rac1 GTP-Binding Protein / blood
  • rac1 GTP-Binding Protein / genetics

Substances

  • Carrier Proteins
  • Enzyme Inhibitors
  • Fibrinolytic Agents
  • Neuropeptides
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Membrane Glycoproteins
  • RAC1 protein, human
  • Rac1 protein, mouse
  • Reactive Oxygen Species
  • collagen-related peptide
  • platelet membrane glycoprotein VI
  • CYBB protein, human
  • Cybb protein, mouse
  • NADPH Oxidase 2
  • Thrombin
  • rac1 GTP-Binding Protein